How Moderna Rigged Its COVID-19 Vaccine Trials To Falsely Show Effectiveness – Great Mountain Publishing


by Edward Hendrie, The Duran:

Dr. David Martin reveals that Moderna concealed the evidence that their vaccine was ineffective by waiting 14 days to perform a confirmatory RT-PCR test on the test subjects. The Moderna study shows that within 7 days of both the first and the second vaccinations, the group receiving the Moderna COVID-19 vaccines displayed greater systemic symptoms of COVID-19 than did the control group. But Moderna ignored those systemic COVID-19 symptoms by reporting them not as symptoms of COVID-19 caused by the vaccine but systemic adverse reactions to the vaccine. Attached below is the study that was presented to the FDA by Moderna to obtain an Emergency Use Authorization from the FDA for the Moderna COVID-19 Vaccination.



Moderna was able to avoid reporting the COVID-19 systemic symptoms caused to the vaccine recipients within 7 days of receiving the first and the second vaccinations as being “confirmed COVID-19 cases” by not testing the vaccine recipients with the RT-PCR test during that time.  By not performing the RT-PCR test, Moderna was able to report the COVID-19 symptoms during that 7 day period under a category of “systemic adverse reactions” to the vaccine instead of “systemic symptoms” of COVID-19 caused by the vaccine that were confirmed COVID-19 cases. Moderna did not do any confirmatory RT-PCR tests on the test subjects until 14 days following the second vaccination. Thus, by waiting until 14 days after the second vaccination to conduct the confirmatory RT-PCR tests, Moderna was able to report that their vaccine was 94.1% (interim results were 94.5%) effective in preventing COVID-19.

The 94.5 % interim efficacy results for the Moderna COVID-19 mRNA vaccine reported by the FDA is misleading because they are not telling you that is a relative risk reduction and not a total risk reduction.

In the Moderna study, the subsequent COVID-19 infection rate for the vaccinated group was .0359%. The COVID-19 infection rate for the placebo group was .6483%. That means that the rate of those who were infected by COVID-19 after receiving the vaccine was reduced by .6124% as compared to those who were infected by COVID-19 after receiving a placebo (.6483% – .0359% = .6124%). Thus, the vaccine has an efficacy of .6124%. One can expect that there will be a reduction of .6124% in COVID-19 infections in the population after being vaccinated. Out of a group of 10,000 people who are vaccinated with the Moderna mRNA COVID-19 vaccine, there will be approximately sixty-one (61) fewer illnesses from COVID-19.

But that is not how Moderna reported the results. Instead of a .6124% efficacy rate, which is the total efficacy rate, Moderna reported a 94.5% efficacy rate, which is a relative efficacy rate. The relative efficacy rate is misleading because it gives the false impression that out of 10,000 people, 9,450 people would be protected from getting COVID-19. How did Moderna come up with the 94.5% figure? They divided the rate of subsequent COVID-19 infection in the vaccinated group (.0359%) by the rate of subsequent COVID-19 infection in the placebo group (.6483%) and then subtracted that difference (.0554) from one (1) to arrive at (.9446). After rounding the FDA reported the interim effectiveness for the Moderna mRNA COVID-19 vaccine of 94.5%. But that is not the total efficacy, which is what people want to know. That 94.5% figure is a relative risk reduction, which is different from a total risk reduction.

The false impression given by that figure is that the vaccine will effectively protect 9,450 out of 10,000 people from COVID-19. In reality, 9,935 are at no risk of getting COVID-19 (10,000 – 65 = 9,935). That means that out of every 10,000 people to get vaccinated with the COVID-19 vaccine it will only prevent sixty-one (61) people from becoming ill from COVID-19 (65 – 4 = 61). According to the study, a total of only 65 people out of every 10,000 are at risk to get COVID-19, and the vaccine will only protect 61 of those 65 people. That is a total efficacy rate for the vaccine of only .6124 % (61 people out of 10,000) and not 94.5 % (9,450 people out of 10,000) as suggested by Moderna.

Furthermore, Moderna limited the measure of efficacy for their COVID-19 vaccine as follows: “The primary efficacy endpoint was efficacy of the vaccine to prevent protocol-defined COVID-19 occurring at least 14 days after the second dose in participants with negative SARS-CoV-2 status at baseline.”

What is a confirmed COVID-19 case? Moderna defined it thusly in its study submitted to the FDA:

For the primary efficacy endpoint, the case definition for a confirmed COVID-19 case was defined as:
• At least TWO of the following systemic symptoms: Fever (≥38ºC), chills, myalgia, headache, sore throat, new olfactory and taste disorder(s), or
• At least ONE of the following respiratory signs/ symptoms: cough, shortness of breath or difficulty breathing, OR clinical or radiographical evidence of pneumonia; and
• NP swab, nasal swab, or saliva sample (or respiratory sample, if hospitalized) positive for SARS-CoV-2 by RT-PCR.

Id. at 13.

Notice in the chart below the systemic symptoms for COVID-19 (fever, chills, myalgia, and headache) were significantly greater within 7 days of the second vaccination. But Moderna did not perform any confirmatory RT-PCR test during that period. Consequently, those systemic symptoms of COVID-19 were reported not as systemic symptoms of COVID-19 caused by the vaccine that were confirmed COVID-19 cases but as “systemic adverse reactions” to the vaccine.

Read More @